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Abstract 
Donepezil (Aricept) is a reversible acetylcholinesterase inhibitor 
which is indicated for the treatment of mild to moderate dementia of 
the Alzheimer's type. We did a retrospective analysis of 41 elderly 
Alzheimer's subjects of different ethnic groups including a large 
number of Asian and Hawaiian patients. Donepezil appears to be 
clinically effective in patients of different ethnicities with mild to 
moderate Alzheimer's disease, even at advanced age. 
Introduction 
Alzheimer's disease is the most common disorder causing cognitive 
decline. It affects approximately 4 million persons in the United 
States. 1 Some of the cognitive signs and symptoms of Alzheimer's 
disease are attributed to a deficiency of cholinergic neurotransmis-
sion.2·5 Donepezil (Aricept ), a reversible acetylcholinesterase in-
hibitor, is indicated for the treatment of mild to moderate dementia 
of the Alzheimer's type. 6•7 
Published studies have not addressed the effectiveness of donepezil 
in Asian and Hawaiian populations. This study was done to evaluate 
the effectiveness of donepeziton cognitive and functional levels in 
mild to moderate Alzheimer's disease among the different ethnic 
groups in Hawaii. 
Methods 
Subjects 
Subjects in this study include male and female elderly of different 
ethnic backgrounds who were referred to the Geriatrics Consulta-
tion Clinic at Kaiser Permanente, Honolulu, Hawaii. Patients who 
were diagnosed as having Alzheimer's Disease were classified as 
mild (>19), moderate (14-19) and severe (<14) based on Folstein 
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Mini Mental Status Examination (MMSE) scores(8). Patients who 
had mild to moderate Alzheimer's and who didn't have any con-
traindication to the use of donepezil were offered this medication. 
Donepezil was initiated in 41 patients. 
Study Design 
This is a retrospective analysis of all patients who were placed on 
donepezil between March 1997 and June 1998. Patients received 
donepezil 5 mg once daily for 1 month, after which they were 
increased to 10 mg once daily. MMSE and Clock Drawing Test (9) 
scores were evaluated at 3 month intervals. Functional and behav-
ioral status were also assessed at 3 months intervals. Analysis was 
done using simple analytic methods. 
Results 
Out of 41 subjects who were on donepezil, 13 (32%) were males and 
28(68%) were females. Eight (20%) of subjects were 65-75 years 
old, 23 (56%) were 76-85 years old and 10 (24%) were >85 years 
old. The mean age of subjects was 80 years. 
Baseline MMSE scores ranged from 14-27,with a mean of 21.5 
(Fig 1). 12 subjects (29%) were assessed for at least 9 months, 
11subjects (27%) for at least6 months, 15 subjects (37%) for at least 
3 months and 3 subjects (7%) for 1 month. Three subjects who were 
assessed for 1 month didn't have a follow up MMSE at the end of 
1 month. MMSE scores improved (>2) in 12 subjects (29% ). MMSE 
scores did not change ( ±_2) from baseline in 15 (37%) of subjects. 
There were no functional or behavioral declines in the 12 subjects 
continuing donepezil for~ 9 months. The responses to donepezil in 
the 3 months ,6 months and 9 months follow up groups, are shown 
in Table 1. Trends ofMMSE scores in the 9 month follow up group 
is shown in Figure 2. 
Among the subjects 9 (22%) were Japanese, 9 (22%) were 
Chinese, 11 (26%) were Caucasian and 12 (29%) were Hawaiian. 
Chinese subjects had a mean change in MMSE by+ 3. 73 , Caucasian 
+ 1.00 , Japanese + 0.92, and Hawaiian + 0.00 at 3 months. 
Out of 41 subjects (24%), 10 had side effects. (Table 2). Three 
subjects had agitation. Two had gross loss in weight (>10 lbs). 
Fifteen (35%) had clinically insignificant weight loss ( <3 lbs) . 
Nineteen subjects (46%) discontinued donepezil at or within 6 
months (Table 3). The reasons for stopping the medication were side 
effects 8 ( 19% ), family's wishes not to continue 3(7% ), no cognitive 
improvement or cognitive decline 4 (10%) and non compliance 
1(2%). 
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Figure 1.— Baseline MMSE score ranges in the subjects on the study Table 1.— Responses to Donepezil
Figure 2.—Trends in MMSE with Donepezil therapy over 9 months
Trends in MMSE scores in 9 months
U,
0
C)
U,
LU
Cl)
30
1I
0 0\\c .‘
Q
Duration of donepezil intake
h Responders
; - Non responder
I3
2
________________
U)
4-
C)
4-
Cu
0
45
0
19-23 23-27
Baseline MMSE Score
14-18
Duration of donepezil therapy Mean Baseline Post intervention
MMSE score MMSE score
3 months- All subjects (15) 20.4 ± 3.6 21.7 ± 4.1
Responders (11) 20.8±3.0 23.2±3.5
Non responders(4) 19.0 ± 4.5 16.0+3.7
6 months- All subjects (11) 22.3 ± 1.9 22.7 ± 4.1
Responders (8) 22.0 ± 2.1 24.5 t3.7
Non responders (3) 22.7 ± 1.2 19.0 tO.8
9 months- All subjects (12) 22.3 ± 2.9 22.2 ÷4.09
Responders (8) 22.5 ± 2.2 24.4 t2.5
Non responders (4) 22.0 ± 3.9 17.8 ± 2.9
Table 2.— Side effects of Donepezil in this study
Side Effect Number
Agitation 3
Gross Weight Loss 2
Visual Hallucination 1
Vomiting 1
Diarrhea 1
Severe Depression 1
Insomnia 1
Table 3.— Reasons for discontinuation of Donepezil treatment
Reasons imo 3mo JDQ
Due to side effects 2 3 3
Family’s wishes - 3 -
Unknown 1 1 1
No Cogn Improvement - 2
Cognitive Decline - 1 1
Non-compliance
- 1 -
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Discussion
To our knowledge, this is the first study which assesses and
compares the effectiveness of donepezil in different ethnic groups.
The results presented herein, demonstrate that donepezil appears to
be clinically effective in patients of different ethnicities with mild to
moderate Alzheimer’ s disease, even at advanced age. MMSE
scores improved (> +2)or did not change (±2) from baseline in 66%
of subjects in this study. Donepezil was well tolerated and continued
for at least 6 months in 56% of subjects in this study.
Previously published trials utilized ADAS-cog, CIBIC plus,
MMSE, CDS-SB. and IDDD to measure efficacy of donepezil)oN
However, the Folstein Mini Mental Status Examination is the most
commonly used tool in clinical practice. This paper suggests the
likely impact of donepezil on Folstein scores in patients with mild
to moderate Alzheimer’s disease. Age does not appear to be a factor
in its effectiveness.
The limitations of this study includes its retrospective nature,
different periods of follow up and the lack of a control group of
untreated subjects.
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It’s not just the salsa. In Pueblo, the free information is also hot. You can et it by dipping into the Consumer
Information Center web site, www.pueblo.sa.ov. Or calling toll-free 1-888-8 PUEBLO (1-888-878-3256) to order
the free Catalog. Either way, you can spice up your life with ready-to-use government information on topics like
investing for retirement, ettin federal benefits, raising healthy children and buying surplus government property.
So remember, if you want information, mild, chunky or otherwise, Pueblo is all you need to know. Sorry, salsa
not available through the Consumer Information Catalog or web site.
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fr4 A public service of this publication and the Consumer Information Center of the U.S. General Services Administration.
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